Médecine des Maladies Métaboliques,
Год журнала:
2023,
Номер
17(8), С. 8S38 - 8S42
Опубликована: Дек. 1, 2023
Le
nombre
de
personnes
âgées
vivant
avec
un
diabète
type
1
(DT1)
augmente
graduellement
depuis
nombreuses
années.
La
prise
en
charge
ces
patients
relève
spécificités
cliniques
et
thérapeutiques.
Outre
les
complications
micro-
macroangiopathiques,
il
convient
rechercher
spécifiquement
troubles
cognitifs
syndromes
gériatriques.
Les
hypoglycémies,
particulier
hypoglycémies
non
ressenties,
devront
systématiquement
être
évaluées.
Sur
le
plan
thérapeutique,
recommandations
internationales
promeuvent
recours
à
la
mesure
continue
du
glucose.
L'utilisation
pompe
insuline
plus
récemment
boucle
fermée
peuvent
envisagées.
Il
bien
identifier
notamment
dans
instituts
médicalisés
afin
leur
apporter
une
spécifique
adaptée.
The
number
of
elderly
people
living
with
diabetes
has
been
gradually
increasing
for
many
years.
management
these
involves
specific
clinical
and
therapeutic
considerations.
In
addition
to
the
micro
macro
vascular
complications,
cognitive
disorders
geriatric
need
be
specifically
investigated.
Hypoglycaemia,
particularly
unawareness
hypoglycaemia,
should
systematically
evaluated.
terms
treatment,
international
recommendations
promote
continuous
glucose
monitoring.
use
insulin
pumps
and,
more
recently,
hybrid
closed
loop
systems
may
also
considered.
These
clearly
identified,
in
medical
institutes,
so
that
they
can
receive
specific,
appropriate
care.
BMJ,
Год журнала:
2024,
Номер
unknown, С. e078432 - e078432
Опубликована: Июнь 12, 2024
Abstract
Objectives
To
estimate
the
burden,
trends,
and
inequalities
of
type
1
diabetes
mellitus
(T1DM)
among
older
adults
at
global,
regional,
national
level
from
1990
to
2019.
Design
Population
based
study.
Adults
aged
≥65
years
21
regions
204
countries
territories
(Global
Burden
Disease
Risk
Factors
Study
2019)
Main
outcome
measures
Primary
outcomes
were
T1DM
related
age
standardised
prevalence,
mortality,
disability
adjusted
life
(DALYs),
average
annual
percentage
change.
Results
The
global
prevalence
increased
400
(95%
uncertainty
interval
(UI)
332
476)
per
100
000
population
in
514
(417
624)
2019,
with
an
trend
0.86%
confidence
(CI)
0.79%
0.93%);
while
mortality
decreased
4.74
UI
3.44
5.9)
3.54
(2.91
4.59)
population,
−1.00%
CI
−1.09%
−0.91%),
DALYs
113
89
137)
103
(85
127)
−0.33%
−0.41%
−0.25%).
most
significant
decrease
was
observed
those
<79
years:
65-69
(−0.44%
year
−0.53%
−0.34%)),
70-74
(−0.34%
(−0.41%
−0.27%)),
75-79
(−0.42%
(−0.58%
−0.26%)).
Mortality
fell
13
times
faster
a
high
sociodemographic
index
versus
low-middle
(−2.17%
−2.31%
−2.02%)
v
−0.16%
(−0.45%
0.12%)).
While
highest
remained
income
North
America,
Australasia,
western
Europe,
DALY
rates
found
southern
sub-Saharan
Africa,
Oceania,
Caribbean.
A
fasting
plasma
glucose
risk
factor
for
during
1990-2019.
Conclusions
expectancy
people
has
since
1990s
along
considerable
associated
DALYs.
lower
women
years,
living
index,
years.
Management
remains
major
challenge
T1DM,
targeted
clinical
guidelines
are
needed.
Journal of Diabetes Science and Technology,
Год журнала:
2024,
Номер
18(4), С. 808 - 818
Опубликована: Май 7, 2024
The
older
population
is
increasing
worldwide
and
up
to
30%
of
adults
have
diabetes.
Older
with
diabetes
are
at
risk
glucose-related
acute
chronic
complications.
Recently,
mostly
in
type
1
(T1D),
continuous
glucose
monitoring
(CGM)
devices
proven
beneficial
improving
time
range
(TIR
glucose,
70-180
mg/dL
or
3.9-10
mmol/L),
glycated
hemoglobin
(HbA1c),
lowering
hypoglycemia
(time
below
[TBR]
<70
<3.9
mmol/L).
international
consensus
group
formulated
CGM
glycemic
targets
relating
based
on
very
limited
data.
Their
recommendations,
expert
opinion,
were
aimed
mitigating
all
adults.
However,
a
heterogeneous
group,
ranging
from
healthy
complex
frail
individuals
chronological,
biological,
functional
aging.
Recent
clinical
trial
real-world
data,
T1D,
demonstrated
that
often
achieve
targets,
including
TIR
recommended
for
non-vulnerable
groups,
but
less
meet
the
TBR
<1%.
Existing
data
also
support
avoidance
may
be
more
strongly
related
minimization
variability
(coefficient
variation
[CV])
rather
than
lower
TIR.
Very
available
goals
adjusted
complexity
their
health
status.
Herein,
we
review
bidirectional
associations
between
status
diabetes;
use
technologies,
impact
control;
discuss
current
guidelines;
propose
new
set
insulin-treated
individualized
living
Advanced Biology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 6, 2025
Abstract
SIRT6
is
a
NAD
+
‐dependent
histone
deacetylase
with
crucial
roles
in
controlling
DNA
damage
repair,
telomere
homeostasis,
oxidative
stress,
autophagy,
and
other
cellular
processes,
it
has
long
been
recognized
as
longevity‐associated
protein.
This
review
details
its
anti‐aging‐related
mechanisms.
First,
facilitates
repair
pathways
maintains
genome
stability
by
deacetylating
H3
at
K56,
K9,
K18
residues,
addition
to
participating
through
mono‐ADP‐ribosylation
Second,
preserves
integrity
mitigates
senescence
reducing
stress‐induced
the
regulation
of
reactive
oxygen
species
(ROS),
inhibition
inflammation,
pathways.
Furthermore,
promotes
slowing
via
modulation
various
signaling
pathways,
including
AMPK,
IGF‐Akt‐mTOR,
H133Y,
IL‐1β,
mitochondrial
autophagy‐related
proteins.
Finally,
regulates
multiple
such
asNF‐κB,
FOXO,
counteract
aging
process.
particularly
delves
into
interplay
between
diseases,
tumors,
cardiovascular
diseases
(e.g.,
atherosclerosis,
heart
failure),
metabolic
type
2
diabetes,
dyslipidemia,
gluconeogenesis,
osteoporosis),
neurodegenerative
Alzheimer's
disease).
Moreover,
recent
advancements
SIRT6‐regulated
compounds
C3G,
BZBS,
Fisetin,
FNDC5,
Lycorine
hydrochloride,
Ergothioneine)
are
discussed
potential
therapeutic
agents
for
these
mediated
diseases.
Diabetes Technology & Therapeutics,
Год журнала:
2023,
Номер
26(5), С. 313 - 323
Опубликована: Дек. 29, 2023
Few
studies
have
evaluated
the
implications
of
alarm
thresholds
continuous
glucose
monitoring
(CGM)
systems
for
individuals
with
diabetes.
The
present
study
aimed
to
investigate
influence
hypoglycemia
and
hyperglycemia
on
glycemic
control
in
adults
type
1
diabetes
(T1DM)
characteristics
patients
who
use
these
alarms
more
frequently.
Diabetes Technology & Therapeutics,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 17, 2024
We
analyzed
the
effect
of
implementing
a
flash
glucose
monitoring
(FGM)
technology
in
public
health
care
system
with
universal
coverage
on
rate
severe
hypoglycemia
requiring
urgent
adults
type
1
diabetes
mellitus
(T1DM).
